ClinicalTrials.gg
CompletedNCT01118273Updated Jun 8, 2015Results posted

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine

A Phase 4 interventional study of Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg and Naproxen Sodium 440 mg (BAYH6689) in Sleep, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 16 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-06-08.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
16 Years to 45 Years
Sex
All
01

Study summary

The objectives of the study are to evaluate the analgesic and hypnotic efficacy of naproxen sodium and diphenhydramine combination when compared to naproxen sodium, diphenhydramine, and an ibuprofen and diphenhydramine combination

02

Conditions studied

  • Sleep

Keywords

  • Naproxen sodium
  • Diphenhydramine
  • Drugs, Investigational
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, male and female volunteers between 16-45 years of age;
  • Scheduled to undergo surgical removal of 1 to 3 impacted third molars, one of which must be at least a partial bony mandibular impaction;
  • Have moderate to severe postoperative pain on the Categorical Pain Rating Scale and a score of >/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale by 2030 h +/- 15 minutes on the day of surgery;
  • Female subjects of must be using a medically acceptable form of for at least 1 month prior to screening (3 months on oral contraceptives), e.g. oral or patch contraceptives, intrauterine device, Depo-Provera, or double-barrier and have a negative pregnancy test at Screening and prior to surgery. Female subjects of nonchildbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy;
  • Provide a personally signed and dated indicating that the subject has been informed of all pertinent aspects of the trial, (subjects \<18 years of age must sign a written assent and have parental or guardian consent).

Exclusion criteria

Exclusion Criteria:

  • History of to naproxen, diphenhydramine, nonsteroidal antiinflammatory drugs (NSAIDS), tramadol, aspirin or any other antihistamine and similar pharmacological agents or components of the products;
  • Evidence or history of (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or within the last 5 years;
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study in the judgment of the investigator;
  • Current or past history of bleeding disorder(s);
  • Acute illness or local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator;
  • Chronic use of antihistamines defined as using 5 or more times a week for 2 or more consecutive weeks during the past 3 months;
  • Positive alcohol breathalyzer test and negative urine drug test prior to surgery;
  • Females who are pregnant or lactating;
  • Chronic or severe sleep problems that do not respond to Over the counter (OTC) medication and requires a prescription hypnotic or sedative;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg

    Drug: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg

  • Active comparator
    Naproxen Sodium 440 mg (BAYH6689)

    Drug: Naproxen Sodium 440 mg (BAYH6689)

  • Experimental
    Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg

    Drug: Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg

  • Active comparator
    Naproxen Sodium 220 mg (BAYH6689)

    Drug: Naproxen Sodium 220 mg (BAYH6689)

  • Active comparator
    DPH 50mg

    Drug: DPH 50mg

  • Active comparator
    Ibuprofen 400 mg / Diphenhydramine citrate 76 mg

    Drug: Ibuprofen 400 mg / Diphenhydramine citrate 76 mg

Interventions

  • DrugNaproxen Sodium 440 mg (BAYH6689) / DPH 50mg

    Drug page: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.

  • DrugNaproxen Sodium 220 mg (BAYH6689) / DPH 50mg

    Drug page: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.

  • DrugDPH 50mg

    Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.

  • DrugIbuprofen 400 mg / Diphenhydramine citrate 76 mg

    Drug page: IbuprofenStudies of IbuprofenIbuprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.

06

What researchers measure

Primary outcomes

  1. Total Sleep Time Measured by Actigraphy

    Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. In calculating the total sleep time, subjects who took rescue medication were treated as "awake" from the time the rescue medication was given until the end of the sleep period. In addition, if subjects rescued before sleep onset, their total sleep time was set to zero.

    Time frame: Up to 10 hours

Secondary outcomes

  1. Wake After Sleep Onset (WASO) Measured by Actigraphy

    Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. WASO was defined as minutes of awake during the period of sleep onset and offset, where sleep onset is the first 20-minute block with 19 minutes of sleep.

    Time frame: Up to 10 hours

  2. Sleep Latency Measured by Actigraphy

    Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Sleep latency was defined as minutes to sleep onset since dosing, where sleep onset was the first 20-minute block with 19 minutes of sleep. For subjects who had not achieved sleep onset (e.g., due to taking rescue medication before achieving sleep onset), sleep latency was considered as censored at the time of wakening.

    Time frame: Up to 10 hours

  3. Global Assessment of Study Medication as a Sleep-aid

    Subject rating of following question with 0 being poor to 4 being excellent: How would you rate the study medication you received as a sleep aid?

    Time frame: Up to 10 hours

  4. Karolinska Sleep Diary - Sleep Quality

    Subject rating of following question with 1 being very poor and 5 being very good: How was your sleep?

    Time frame: Up to 10 hours

  5. Karolinska Sleep Diary - Calmness of Sleep

    Subject rating of following question with 1 being very restless and 5 being very calm: How calm was your sleep?

    Time frame: Up to 10 hours

  6. Karolinska Sleep Diary - Easiness to Fall Asleep

    Subject rating of following question with 1 being very difficult to 5 being very easy: How easy was it to fall asleep?

    Time frame: Up to 10 hours

  7. Karolinska Sleep Diary - Premature Awakening

    Subject rating of following question with 1 being woke up much too early to 3 being no: Premature awakening?

    Time frame: Up to 10 hours

  8. Karolinska Sleep Diary - Ease of Awakening

    Subject rating of following question with 1 being very difficult to 5 being very easy: Ease of awakening?

    Time frame: Up to 10 hours

  9. Karolinska Sleep Diary - Well Rested

    Subject rating of following question with 1 being not rested at all to 3 being completely rested: Well-rested?

    Time frame: Up to 10 hours

  10. Karolinska Sleep Diary - Sufficient Sleep

    Subject rating of following question with 1 being no, definitely too little to 5 being yes, definitely enough: Did you get enough (sufficient) sleep?

    Time frame: Up to 10 hours

  11. Total Sleep Time by Subject Assessment

    Subject responded to: Please estimate the number of hours and minutes you think that you slept.

    Time frame: Up to 10 hours

  12. Sleep Quality Index

    Sleep Quality Index is the mean score of items, 'sleep quality', 'calm sleep', 'ease falling asleep', and 'slept throughout' on the Karolinska Sleep Diary, ranges from 1 (worst possible) to 5 (best possible).

    Time frame: Up to 10 hours

  13. Overall Rating of Severity in Categorical Pain Rating Scale Score

    Subject responded to question, 'My pain at this time is' by selecting one of the following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3).

    Time frame: Up to 10 hours

  14. Change From Baseline in Categorical Pain Rating Scale Score

    Subjects responded to question, 'My pain at this time is' with following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3). Subjects completed this question at baseline (post-dental surgery) and after sleep period. The following measure is the change in pain rating from baseline.

    Time frame: Baseline and up to 10 hours

  15. Overall Rating of Severity in Visual Analog Scale (VAS) Score

    Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.

    Time frame: At 10 hours

  16. Change From Baseline in Visual Analog Scale (VAS) Score

    Subjects completed the VAS scale at baseline (post-dental surgery) and after completion of the sleep period. Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.This measure indicates the change in pain severity rating on the VAS scale from baseline.

    Time frame: Baseline and up to 10 hours

  17. Overall Rating of Pain Relief

    Subjects responded to question, "Overall, the relief from my starting pain was" by checking one of the following choices: no relief (0), a little relief (1), some relief (2), a lot of relief (3), complete relief (4).

    Time frame: Up to 10 hours

  18. Time to Rescue Medication

    Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the time to taking rescue medication from the time the subject took study treatment.

    Time frame: Up to 10 hours

  19. Cumulative Proportion of Participants Taking Rescue Medication by Hour

    Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the proportion of subjects who rescued in the study.

    Time frame: Up to 10 hours

  20. Global Assessment of Study Medication as a Pain Reliever

    Subject responded to question, 'How would you rating this study medication you received as a pain-reliever?' with the following choices: Poor (0), Fair(1), Good(2), Very Good(3), Excellent(4)

    Time frame: Up to 10 hours

  21. Number of Times Participants Took Rescue Medication

    Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the number of times rescue medication was taken by a subject.

    Time frame: Up to 10 hours

  22. Total Wake Time Measured by Actigraphy

    Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

    Time frame: Up to 10 hours

  23. Sleep Efficiency Measured by Actigraphy

    Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

    Time frame: Up to 10 hours

  24. Activity Mean Measured by Actigraphy

    Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Activity mean - average movement per minute.

    Time frame: Up to 10 hours

  25. Wake Episode Measured by Actigraphy

    Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Wake Episodes - # of blocks of continuous wake epochs (defined as 2 or more consecutive epochs scored as wake that ends when there is at least one epoch scored as sleep subsequent to the start of the wake epochs).

    Time frame: Up to 10 hours

07

Results

Posted Jun 17, 2014

Participant flow

Participant flow — Overall Study
MilestoneNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Started272727272727
Completed272727272727
Not completed000000

Outcome measures

PrimaryTotal Sleep Time Measured by Actigraphy

Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. In calculating the total sleep time, subjects who took rescue medication were treated as "awake" from the time the rescue medication was given until the end of the sleep period. In addition, if subjects rescued before sleep onset, their total sleep time was set to zero.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Minutes
Total Sleep Time Measured by Actigraphy
MinutesNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Total Sleep Time Measured by Actigraphy339.80 (259 to 420)304.60 (224 to 385)413.89 (333 to 494)308.89 (228 to 389)76.35 (-4 to 157)335.68 (254 to 417)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.54
SecondaryWake After Sleep Onset (WASO) Measured by Actigraphy

Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. WASO was defined as minutes of awake during the period of sleep onset and offset, where sleep onset is the first 20-minute block with 19 minutes of sleep.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Minutes
Wake After Sleep Onset (WASO) Measured by Actigraphy
MinutesNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Wake After Sleep Onset (WASO) Measured by Actigraphy139.96 (70 to 210)190.91 (121 to 261)75.66 (7 to 144)145.67 (72 to 219)428.34 (351 to 506)129.02 (59 to 199)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.31
SecondarySleep Latency Measured by Actigraphy

Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Sleep latency was defined as minutes to sleep onset since dosing, where sleep onset was the first 20-minute block with 19 minutes of sleep. For subjects who had not achieved sleep onset (e.g., due to taking rescue medication before achieving sleep onset), sleep latency was considered as censored at the time of wakening.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Minutes
Sleep Latency Measured by Actigraphy
MinutesNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Sleep Latency Measured by Actigraphy29.17 (9 to 50)32.81 (12 to 53)46.77 (27 to 67)31.58 (10 to 53)41.05 (18 to 64)36.38 (16 to 57)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs DPH 50mg · Log Rank · p = 0.45
SecondaryGlobal Assessment of Study Medication as a Sleep-aid

Subject rating of following question with 0 being poor to 4 being excellent: How would you rate the study medication you received as a sleep aid?

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Global Assessment of Study Medication as a Sleep-aid
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Poor162460
Fair443676
Good877639
Very good548327
Excellent413100
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs DPH 50mg · Cochran-Mantel-Haenszel · p = 0.001
SecondaryKarolinska Sleep Diary - Sleep Quality

Subject rating of following question with 1 being very poor and 5 being very good: How was your sleep?

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Sleep Quality
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
1 = Very poor141110
2 = Rather poor202251
3 = Neither poor nor good61137310
4 = Rather good11514999
5 = Very good223102
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs DPH 50mg · ANCOVA · p = 0.05
SecondaryKarolinska Sleep Diary - Calmness of Sleep

Subject rating of following question with 1 being very restless and 5 being very calm: How calm was your sleep?

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Calmness of Sleep
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
1 = Very restless021110
2 = Rather restless176577
3 = Neither restless nor calm543735
4 = Rather calm16612668
5 = Very calm031112
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs DPH 50mg · ANCOVA · p = 0.019
SecondaryKarolinska Sleep Diary - Easiness to Fall Asleep

Subject rating of following question with 1 being very difficult to 5 being very easy: How easy was it to fall asleep?

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Easiness to Fall Asleep
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
1 = Very difficult051310
2 = Rather difficult332565
3 = Neither difficult nor easy101111377
4 = Rather easy828749
5 = Very easy111201
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.018
SecondaryKarolinska Sleep Diary - Premature Awakening

Subject rating of following question with 1 being woke up much too early to 3 being no: Premature awakening?

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Premature Awakening
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
1 = Woke up much too early562685
2 = Woke up somewhat too early810127613
3 = No969744
Statistical analysis
  • Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg vs DPH 50mg · Cochran-Mantel-Haenszel · p = 0.03
SecondaryKarolinska Sleep Diary - Ease of Awakening

Subject rating of following question with 1 being very difficult to 5 being very easy: Ease of awakening?

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Ease of Awakening
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
1 = Very difficult010100
2 = Rather difficult102110
3 = Neither difficult nor easy175134
4 = Rather easy158815914
5 = Very easy568254
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs DPH 50mg · Cochran-Mantel-Haenszel · p = 0.76
SecondaryKarolinska Sleep Diary - Well Rested

Subject rating of following question with 1 being not rested at all to 3 being completely rested: Well-rested?

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Well Rested
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
1 = Not rested at all140031
2 = Somewhat unrested131414121417
3 = Completely rested849814
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs DPH 50mg · ANCOVA · p = 0.015
SecondaryKarolinska Sleep Diary - Sufficient Sleep

Subject rating of following question with 1 being no, definitely too little to 5 being yes, definitely enough: Did you get enough (sufficient) sleep?

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Sufficient Sleep
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
1 = No, definitely too little140121
2 = No, much too little432141
3 = No, somewhat too little443486
4 = Yes, almost enough1081410412
5 = Yes, definitely enough334402
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs DPH 50mg · Cochran-Mantel-Haenszel · p = 0.04
SecondaryTotal Sleep Time by Subject Assessment

Subject responded to: Please estimate the number of hours and minutes you think that you slept.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Minutes
Total Sleep Time by Subject Assessment
MinutesNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Total Sleep Time by Subject Assessment306.32 (231 to 381)309.97 (235 to 385)339.08 (264 to 414)309.23 (234 to 384)160.49 (85 to 236)299.58 (223 to 376)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.95
SecondarySleep Quality Index

Sleep Quality Index is the mean score of items, 'sleep quality', 'calm sleep', 'ease falling asleep', and 'slept throughout' on the Karolinska Sleep Diary, ranges from 1 (worst possible) to 5 (best possible).

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Scores on a scale
Sleep Quality Index
Scores on a scaleNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Sleep Quality Index3.49 (3.1 to 3.9)2.89 (2.5 to 3.3)3.40 (3.0 to 3.8)3.12 (2.7 to 3.5)2.96 (2.6 to 3.4)3.37 (3.0 to 3.7)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs DPH 50mg · Cochran-Mantel-Haenszel · p = 0.05
SecondaryOverall Rating of Severity in Categorical Pain Rating Scale Score

Subject responded to question, 'My pain at this time is' by selecting one of the following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3).

Time frame:
Up to 10 hours
Reported as:
Mean · Scores on a scale
Overall Rating of Severity in Categorical Pain Rating Scale Score
Scores on a scaleNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Baseline2.44 ± 0.512.48 ± 0.512.48 ± 0.512.48 ± 0.512.37 ± 0.492.22 ± 0.42
Post-Baseline1.26 ± 1.021.48 ± 1.051.26 ± 0.941.78 ± 0.972.67 ± 0.621.41 ± 1.01
SecondaryChange From Baseline in Categorical Pain Rating Scale Score

Subjects responded to question, 'My pain at this time is' with following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3). Subjects completed this question at baseline (post-dental surgery) and after sleep period. The following measure is the change in pain rating from baseline.

Time frame:
Baseline and up to 10 hours
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Categorical Pain Rating Scale Score
Scores on a scaleNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Change From Baseline in Categorical Pain Rating Scale Score-1.2 (-1.5 to -0.8)-1.0 (-1.3 to -0.6)-1.2 (-1.5 to -0.8)-0.7 (-1.0 to -0.3)0.3 (-0.1 to 0.6)-0.9 (-1.3 to -0.6)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.42
SecondaryOverall Rating of Severity in Visual Analog Scale (VAS) Score

Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.

Time frame:
At 10 hours
Reported as:
Mean · Scores on a scale
Overall Rating of Severity in Visual Analog Scale (VAS) Score
Scores on a scaleNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Baseline76.11 ± 11.677.26 ± 13.178.19 ± 13.473.70 ± 12.379.15 ± 9.7673.11 ± 10.5
Post-Baseline32.11 ± 31.140.30 ± 33.030.33 ± 28.648.59 ± 33.484.26 ± 19.938.19 ± 32.9
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg · ANCOVA · p = 0.35
SecondaryChange From Baseline in Visual Analog Scale (VAS) Score

Subjects completed the VAS scale at baseline (post-dental surgery) and after completion of the sleep period. Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.This measure indicates the change in pain severity rating on the VAS scale from baseline.

Time frame:
Baseline and up to 10 hours
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Visual Analog Scale (VAS) Score
Scores on a scaleNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Change From Baseline in Visual Analog Scale (VAS) Score-44.04 (-55.1 to -33.0)-36.65 (-47.7 to -25.6)-47.26 (-58.4 to -36.2)-25.89 (-37.0 to -14.8)6.00 (-5.1 to 17.1)-35.89 (-47.0 to -24.8)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.35
SecondaryOverall Rating of Pain Relief

Subjects responded to question, "Overall, the relief from my starting pain was" by checking one of the following choices: no relief (0), a little relief (1), some relief (2), a lot of relief (3), complete relief (4).

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Overall Rating of Pain Relief
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
No relief1326114
A little relief443392
Some relief875455
A lot relief12101311213
Complete relief234303
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.72
SecondaryTime to Rescue Medication

Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the time to taking rescue medication from the time the subject took study treatment.

Time frame:
Up to 10 hours
Reported as:
Median · Minutes
Time to Rescue Medication
MinutesNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Time to Rescue MedicationNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs DPH 50mg · Log Rank · p = 0.001
SecondaryCumulative Proportion of Participants Taking Rescue Medication by Hour

Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the proportion of subjects who rescued in the study.

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Cumulative Proportion of Participants Taking Rescue Medication by Hour
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
1 hour230140
2 hours6959177
3 hours81159207
4 hours1011510217
5 hours1111511247
6 hours1111612259
7 hours11127132510
8 hours11127132510
9 hours11128132511
10 hours12128132511
SecondaryGlobal Assessment of Study Medication as a Pain Reliever

Subject responded to question, 'How would you rating this study medication you received as a pain-reliever?' with the following choices: Poor (0), Fair(1), Good(2), Very Good(3), Excellent(4)

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Global Assessment of Study Medication as a Pain Reliever
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Poor1426155
Fair675475
Good774754
Very good11499011
Excellent257102
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · Cochran-Mantel-Haenszel · p = 0.35
SecondaryNumber of Times Participants Took Rescue Medication

Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the number of times rescue medication was taken by a subject.

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Number of Times Participants Took Rescue Medication
ParticipantsNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
015151914216
112128132211
2000030
3000000
SecondaryTotal Wake Time Measured by Actigraphy

Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Minutes
Total Wake Time Measured by Actigraphy
MinutesNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Total Wake Time Measured by Actigraphy253.72 (174 to 333)290.03 (210 to 370)180.21 (100 to 260)285.62 (206 to 365)518.58 (439 to 598)255.20 (175 to 336)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.53
SecondarySleep Efficiency Measured by Actigraphy

Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Percentage of sleep time
Sleep Efficiency Measured by Actigraphy
Percentage of sleep timeNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Sleep Efficiency Measured by Actigraphy57.24 (44 to 71)51.49 (38 to 65)68.87 (55 to 82)52.09 (39 to 66)12.85 (-1 to 26)56.70 (43 to 70)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.55
SecondaryActivity Mean Measured by Actigraphy

Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Activity mean - average movement per minute.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Movement per minute
Activity Mean Measured by Actigraphy
Movement per minuteNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Activity Mean Measured by Actigraphy42.09 (25 to 59)48.48 (32 to 65)26.73 (10 to 43)52.36 (36 to 69)72.43 (56 to 89)41.14 (24 to 58)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.59
SecondaryWake Episode Measured by Actigraphy

Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Wake Episodes - # of blocks of continuous wake epochs (defined as 2 or more consecutive epochs scored as wake that ends when there is at least one epoch scored as sleep subsequent to the start of the wake epochs).

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Wake episodes
Wake Episode Measured by Actigraphy
Wake episodesNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
Wake Episode Measured by Actigraphy8.38 (5 to 11)10.86 (8 to 14)13.26 (10 to 16)9.89 (7 to 13)5.84 (3 to 9)11.98 (9 to 15)
Statistical analysis
  • Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.25

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were collected after the administration of the first dose of study drug up to 5 days post drug administration, or up to 30 days after the last study drug administration if they were serious adverse events (SAEs).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg—0/27 (0%)2/27 (7.4%)
Naproxen Sodium 440 mg (BAYH6689)—0/27 (0%)2/27 (7.4%)
Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg—0/27 (0%)3/27 (11.1%)
Naproxen Sodium 220 mg (BAYH6689)—0/27 (0%)1/27 (3.7%)
DPH 50mg—0/27 (0%)5/27 (18.5%)
Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg—0/27 (0%)1/27 (3.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventNaproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 440 mg (BAYH6689)Naproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mg
NAUSEAGastrointestinal disorders1/271/272/270/272/270/27
VOMITINGGastrointestinal disorders0/270/270/270/272/270/27
ABDOMINAL PAINGastrointestinal disorders0/271/270/270/270/270/27
CONSTIPATIONGastrointestinal disorders0/270/270/270/271/270/27
PYREXIAGeneral disorders0/270/271/270/270/270/27
DIZZINESSNervous system disorders0/270/270/270/271/270/27
HEADACHENervous system disorders0/270/270/270/271/270/27
RESTLESS LEGS SYNDROMENervous system disorders0/270/270/270/271/270/27
INSOMNIAPsychiatric disorders0/270/270/271/270/270/27
PHARYNGOLARYNGEAL PAINRespiratory, thoracic and mediastinal disorders0/270/271/270/270/270/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Naproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mgNaproxen Sodium 440 mg (BAYH6689)Total
Mean19 ± 2.820 ± 2.819 ± 2.019 ± 3.019 ± 2.520 ± 2.619 ± 2.6
Sex: Female, Male
Sex: Female, Male(Participants)Naproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mgNaproxen Sodium 440 mg (BAYH6689)Total
Female16151019121284
Male1112178151578
Baseline Categorical Pain Rating Scale
Baseline Categorical Pain Rating Scale(Participants)Naproxen Sodium 440 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689) / DPH 50mgNaproxen Sodium 220 mg (BAYH6689)DPH 50mgIbuprofen 400 mg / Diphenhydramine Citrate 76 mgNaproxen Sodium 440 mg (BAYH6689)Total
No pain0000000
Mild pain0000000
Moderate pain15141417211495
Severe pain1213131061367
08

Study locations

1 site
  • Salt Lake City, Utah 84124, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 6 years 4 months after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2010
First posted
May 6, 2010
Start
Jan 2008
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results delay requested
May 30, 2012
Results first posted
Jun 17, 2014
Last update
Jun 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01118273
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 6, 2010
Start date
Jan 2008
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Jun 17, 2014
Last update
Jun 8, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion